Feasibility in Identification of Breast Cancer Candidates for Elimination of Axillary Surgery
Breast Cancer
About this trial
This is an interventional diagnostic trial for Breast Cancer focused on measuring neoadjuvant chemotherapy, nodal response, core needle biopsy
Eligibility Criteria
Inclusion Criteria: Clinical stage T1-4 N1-3M0 breast cancer at diagnosis (prior to neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th edition Aged above 18 and below 70 years No other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix Patients must have had estrogen receptor, progesterone receptor and HER2 status (by immunohistochemistry [IHC] and/or in situ hybridization [ISH]) evaluated on core needle biopsy prior to starting neoadjuvant chemotherapy Completing all planned cycles and regimens of neoadjuvant chemotherapy followed by axillary surgery Exclusion Criteria: Nonrepresentative core needle biopsy in the breast during neoadjuvant chemotherapy Inflammatory breast cancer
Sites / Locations
- Zhi-Min Shao
Arms of the Study
Arm 1
Experimental
Ultrasound-Guided Biopsy of Tumor Site during neoadjuvant chemotherapy
For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated CNB (RCNB) was performed after 2-4 cycles of NAC, depending on the total cycles of NAC. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.